BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
Related Research units
Abstract
The ubiquitin-proteasome system emerged as a new therapeutic target in cancer treatment. The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC).
Bibliographical data
| Original language | German |
|---|---|
| Article number | 2 |
| ISSN | 0902-4441 |
| Publication status | Published - 2010 |
| pubmed | 20374272 |
|---|
